ProPhase Labs Net Income
| PRPH Stock | USD 0.16 0.06 27.27% |
As of the 30th of January, ProPhase Labs holds the Risk Adjusted Performance of (0.23), coefficient of variation of (303.50), and Variance of 139.51. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProPhase Labs, as well as the relationship between them.
ProPhase Labs Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.5901 | Revenue | Earnings Share (19.80) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -44.6 M | -42.3 M | |
| Net Income Applicable To Common Shares | 7.2 M | 7.6 M | |
| Net Loss | -44.6 M | -42.3 M | |
| Net Loss | (32.17) | (30.56) | |
| Net Income Per E B T | 1.13 | 1.19 |
ProPhase | Net Income | Build AI portfolio with ProPhase Stock |
The Net Income trend for ProPhase Labs offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether ProPhase Labs is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest ProPhase Labs' Net Income Growth Pattern
Below is the plot of the Net Income of ProPhase Labs over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ProPhase Labs financial statement analysis. It represents the amount of money remaining after all of ProPhase Labs operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ProPhase Labs' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProPhase Labs' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (49.52 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ProPhase Net Income Regression Statistics
| Arithmetic Mean | (7,214,225) | |
| Coefficient Of Variation | (326.41) | |
| Mean Deviation | 15,948,553 | |
| Median | (2,710,000) | |
| Standard Deviation | 23,548,142 | |
| Sample Variance | 554.5T | |
| Range | 95.2M | |
| R-Value | (0.52) | |
| Mean Square Error | 433T | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | (2,413,946) | |
| Total Sum of Squares | 8872.2T |
ProPhase Net Income History
Other Fundumenentals of ProPhase Labs
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ProPhase Labs Net Income component correlations
ProPhase Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ProPhase Labs is extremely important. It helps to project a fair market value of ProPhase Stock properly, considering its historical fundamentals such as Net Income. Since ProPhase Labs' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProPhase Labs' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProPhase Labs' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (19.80) | Revenue Per Share | Quarterly Revenue Growth (0.38) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
ProPhase Labs 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ProPhase Labs' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ProPhase Labs.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in ProPhase Labs on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding ProPhase Labs or generate 0.0% return on investment in ProPhase Labs over 90 days. ProPhase Labs is related to or competes with Aytu BioScience, TherapeuticsMD, Allurion Technologies, Eterna Therapeutics, Biofrontera, Aethlon Medical, and Co Diagnostics. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the cou... More
ProPhase Labs Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ProPhase Labs' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ProPhase Labs upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.33) | |||
| Maximum Drawdown | 69.23 | |||
| Value At Risk | (22.22) | |||
| Potential Upside | 11.11 |
ProPhase Labs Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProPhase Labs' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ProPhase Labs' standard deviation. In reality, there are many statistical measures that can use ProPhase Labs historical prices to predict the future ProPhase Labs' volatility.| Risk Adjusted Performance | (0.23) | |||
| Jensen Alpha | (3.76) | |||
| Total Risk Alpha | (4.74) | |||
| Treynor Ratio | 1.42 |
ProPhase Labs January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.23) | |||
| Market Risk Adjusted Performance | 1.43 | |||
| Mean Deviation | 7.9 | |||
| Coefficient Of Variation | (303.50) | |||
| Standard Deviation | 11.81 | |||
| Variance | 139.51 | |||
| Information Ratio | (0.33) | |||
| Jensen Alpha | (3.76) | |||
| Total Risk Alpha | (4.74) | |||
| Treynor Ratio | 1.42 | |||
| Maximum Drawdown | 69.23 | |||
| Value At Risk | (22.22) | |||
| Potential Upside | 11.11 | |||
| Skewness | 1.27 | |||
| Kurtosis | 6.11 |
ProPhase Labs Backtested Returns
ProPhase Labs maintains Sharpe Ratio (i.e., Efficiency) of -0.34, which implies the firm had a -0.34 % return per unit of risk over the last 3 months. ProPhase Labs exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check ProPhase Labs' Variance of 139.51, coefficient of variation of (303.50), and Risk Adjusted Performance of (0.23) to confirm the risk estimate we provide. The company holds a Beta of -2.75, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ProPhase Labs are expected to decrease by larger amounts. On the other hand, during market turmoil, ProPhase Labs is expected to outperform it. At this point, ProPhase Labs has a negative expected return of -4.18%. Please make sure to check ProPhase Labs' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if ProPhase Labs performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.85 |
Very good predictability
ProPhase Labs has very good predictability. Overlapping area represents the amount of predictability between ProPhase Labs time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ProPhase Labs price movement. The serial correlation of 0.85 indicates that around 85.0% of current ProPhase Labs price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.85 | |
| Spearman Rank Test | 0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 0.1 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ProPhase Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ProPhase Labs reported net income of (49.52 Million). This is 114.51% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 108.67% higher than that of the company.
ProPhase Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProPhase Labs' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProPhase Labs could also be used in its relative valuation, which is a method of valuing ProPhase Labs by comparing valuation metrics of similar companies.ProPhase Labs is currently under evaluation in net income category among its peers.
ProPhase Labs Institutional Holders
Institutional Holdings refers to the ownership stake in ProPhase Labs that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ProPhase Labs' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProPhase Labs' value.| Shares | Virtu Financial Llc | 2025-06-30 | 40.4 K | Two Sigma Securities, Llc | 2025-06-30 | 37.8 K | Bank Of New York Mellon Corp | 2025-06-30 | 37.1 K | United Capital Management Of Ks | 2025-06-30 | 34.7 K | Blackrock Inc | 2025-06-30 | 28 K | Bank Of America Corp | 2025-06-30 | 27.2 K | Northern Trust Corp | 2025-06-30 | 23.2 K | Bkb Wealth Advisors, Llc | 2025-06-30 | 19.6 K | Hpm Partners Llc | 2025-06-30 | 19 K | Vanguard Group Inc | 2025-06-30 | 408.3 K | Geode Capital Management, Llc | 2025-06-30 | 259.1 K |
ProPhase Fundamentals
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (5.40) % | ||||
| Current Valuation | 8.04 M | ||||
| Shares Outstanding | 4.74 M | ||||
| Shares Owned By Insiders | 5.05 % | ||||
| Shares Owned By Institutions | 3.94 % | ||||
| Number Of Shares Shorted | 300.24 K | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 0.11 X | ||||
| Price To Sales | 0.16 X | ||||
| Revenue | 6.77 M | ||||
| Gross Profit | 987 K | ||||
| EBITDA | (32.34 M) | ||||
| Net Income | (49.52 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 24.57 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 1.65 X | ||||
| Cash Flow From Operations | (17.54 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (19.80) X | ||||
| Target Price | 13.8 | ||||
| Number Of Employees | 96 | ||||
| Beta | -0.55 | ||||
| Market Capitalization | 786.34 K | ||||
| Total Asset | 63.2 M | ||||
| Retained Earnings | (58.39 M) | ||||
| Working Capital | (1.5 M) | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
| Net Asset | 63.2 M |
About ProPhase Labs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProPhase Labs's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProPhase Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProPhase Labs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (19.80) | Revenue Per Share | Quarterly Revenue Growth (0.38) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.